Organoids Market Size Report | Analysis and Forecast 2028

[Research Report] The organoids market size is expected to grow from US$ 2,507.28 million in 2022 to US$ 8,121.45 million by 2028; it is estimated to record a CAGR of 21.8% from 2023 to 2028.

The organoids market is segmented based on type, application, source, and geography. The report offers insights and in-depth analysis of the market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across the region.

Strategic Insights

Market Insights

Increasing Demand for Tumor Modeling and Biobanking Drives Organoids Market Growth

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Over the past few decades, organoids have been generated from diverse human cancers associated with breast, colon, pancreas, prostate, bladder, and liver. Studies involving these models help in providing key facts about these malignancies. Due to constant advancements in the current scenario, tumoroid lines are increasingly being passed in vitro, opening new paths for a range of downstream applications. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines. Further, recent research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is propelling the global organoids market.

Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, such innovations are driving market growth.

Type-Based Insights

Based on type, the organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. In 2022, the intestine segment held the largest share of the market and the stomach segment is anticipated to register the highest CAGR during the forecast period.

Organoids Market, by Product Type – 2022–2028

Get more information on this report : Request Free Sample PDF

Application-Based Insights

Based on application, the organoids market is divided into developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. In 2022, the developmental biology held the largest share of the market and drug discovery & personalized medicine is anticipated to register the highest CAGR during the forecast period.

Source-Based Insights

Based on source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2022 and is expected to record at a higher CAGR during the forecast period.

The organoids market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.

• In May 2020, UK-headquartered iPSC disease modeling company DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients.
• In August 2021, InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store.
• In March 2023, Molecular Devices, LLC. and HUB Organoids (HUB), announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Under the terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like the heart and brain.

In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers.

The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.

In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in the Biotechnology and Scientific Instruments field in India.

Company Profiles

• STEMCELL Technologies Inc.
• Cellesce Ltd
• Hubrecht Organoid TechnologY
• Definigen  
• Organoid Therapeutics
• PeproTech, Inc
• Thermo Fisher Scientific Inc  
• Corning Inc
• Merck KGaA
• InSphero